CorMedix (CRMD) Competitors $11.37 +0.01 (+0.09%) Closing price 07/15/2025 04:00 PM EasternExtended Trading$11.32 -0.04 (-0.40%) As of 07/15/2025 07:42 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock CRMD vs. PTGX, VKTX, MLTX, MTSR, MOR, KYMR, IMVT, CRNX, ALVO, and HCMShould you be buying CorMedix stock or one of its competitors? The main competitors of CorMedix include Protagonist Therapeutics (PTGX), Viking Therapeutics (VKTX), MoonLake Immunotherapeutics (MLTX), Metsera (MTSR), MorphoSys (MOR), Kymera Therapeutics (KYMR), Immunovant (IMVT), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), and HUTCHMED (HCM). These companies are all part of the "pharmaceutical products" industry. CorMedix vs. Its Competitors Protagonist Therapeutics Viking Therapeutics MoonLake Immunotherapeutics Metsera MorphoSys Kymera Therapeutics Immunovant Crinetics Pharmaceuticals Alvotech HUTCHMED CorMedix (NASDAQ:CRMD) and Protagonist Therapeutics (NASDAQ:PTGX) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their risk, media sentiment, valuation, institutional ownership, earnings, dividends, analyst recommendations and profitability. Which has better earnings & valuation, CRMD or PTGX? Protagonist Therapeutics has higher revenue and earnings than CorMedix. CorMedix is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCorMedix$43.47M17.74-$17.93M$0.2251.68Protagonist Therapeutics$207.80M16.50$275.19M$0.7573.76 Which has more volatility and risk, CRMD or PTGX? CorMedix has a beta of 1.58, indicating that its share price is 58% more volatile than the S&P 500. Comparatively, Protagonist Therapeutics has a beta of 2.26, indicating that its share price is 126% more volatile than the S&P 500. Does the media refer more to CRMD or PTGX? In the previous week, CorMedix had 2 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for CorMedix and 3 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 1.39 beat CorMedix's score of 0.94 indicating that Protagonist Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment CorMedix 2 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Protagonist Therapeutics 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate CRMD or PTGX? CorMedix currently has a consensus price target of $17.14, suggesting a potential upside of 50.77%. Protagonist Therapeutics has a consensus price target of $66.10, suggesting a potential upside of 19.49%. Given CorMedix's higher possible upside, research analysts plainly believe CorMedix is more favorable than Protagonist Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score CorMedix 0 Sell rating(s) 2 Hold rating(s) 5 Buy rating(s) 1 Strong Buy rating(s) 2.88Protagonist Therapeutics 0 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 3.00 Is CRMD or PTGX more profitable? Protagonist Therapeutics has a net margin of 27.04% compared to CorMedix's net margin of 20.81%. CorMedix's return on equity of 22.57% beat Protagonist Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets CorMedix20.81% 22.57% 17.02% Protagonist Therapeutics 27.04%9.22%8.31% Do insiders & institutionals believe in CRMD or PTGX? 34.2% of CorMedix shares are held by institutional investors. Comparatively, 98.6% of Protagonist Therapeutics shares are held by institutional investors. 5.3% of CorMedix shares are held by company insiders. Comparatively, 4.9% of Protagonist Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth. SummaryProtagonist Therapeutics beats CorMedix on 10 of the 16 factors compared between the two stocks. Get CorMedix News Delivered to You Automatically Sign up to receive the latest news and ratings for CRMD and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding CRMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRMD vs. The Competition Export to ExcelMetricCorMedixMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$770.49M$2.96B$5.61B$9.29BDividend YieldN/A2.43%4.23%4.03%P/E Ratio51.6820.2228.5419.58Price / Sales17.74299.17429.2495.01Price / CashN/A43.1536.0257.93Price / Book8.127.568.145.54Net Income-$17.93M-$55.11M$3.24B$257.73M7 Day Performance0.18%3.81%0.18%-0.08%1 Month Performance-20.71%11.60%5.96%8.09%1 Year Performance127.40%-2.11%26.24%13.02% CorMedix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRMDCorMedix2.6766 of 5 stars$11.37+0.1%$17.14+50.8%+132.0%$770.49M$43.47M51.6830PTGXProtagonist Therapeutics1.452 of 5 stars$49.87-2.3%$66.10+32.5%+50.5%$3.09B$434.43M66.49120Positive NewsVKTXViking Therapeutics4.6204 of 5 stars$27.51-2.4%$87.15+216.8%-48.3%$3.09BN/A-23.9220Upcoming EarningsMLTXMoonLake Immunotherapeutics1.7375 of 5 stars$47.50-2.8%$74.50+56.8%+1.6%$3.04BN/A-20.652MTSRMetseraN/A$28.39-3.6%$55.00+93.7%N/A$2.98BN/A0.0081Gap UpMORMorphoSysN/A$18.96flatN/AN/A$2.86B$238.28M-5.45730KYMRKymera Therapeutics3.0938 of 5 stars$43.81-2.2%$59.11+34.9%-0.2%$2.85B$47.07M-14.13170IMVTImmunovant1.3621 of 5 stars$16.42-3.1%$38.33+133.5%-42.7%$2.81BN/A-5.99120CRNXCrinetics Pharmaceuticals3.4288 of 5 stars$29.06-2.5%$71.75+146.9%-41.2%$2.72B$1.04M-7.61210ALVOAlvotech3.4038 of 5 stars$9.02-1.8%$18.00+99.6%-30.5%$2.72B$491.98M24.381,032HCMHUTCHMED1.6148 of 5 stars$15.42-2.5%$19.00+23.2%-11.4%$2.69B$630.20M0.001,811Gap Down Related Companies and Tools Related Companies PTGX Alternatives VKTX Alternatives MLTX Alternatives MTSR Alternatives MOR Alternatives KYMR Alternatives IMVT Alternatives CRNX Alternatives ALVO Alternatives HCM Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:CRMD) was last updated on 7/16/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredWhy Elon is funding the “Quantum Power Grid”Elon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | SponsoredWhich Gold Miner Trades at 30% of NAV? The One Buffett WantsSome of the world’s best gold developers are trading at just 30% of NAV — like buying a dollar for 30 cents. ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredPost-Halving = Profit Season (Here’s How to Win It)It happens like clockwork. Every four years, the crypto market enters a new phase — and for those who know how...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding CorMedix Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share CorMedix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRMD Stock Alerts